Navigation Links
Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast Cancer
Date:10/21/2013

clinical applications. Taken together, we believe they will shed additional light on more advanced clinical trials and enhance the value of ENMD-2076."  

To view the poster presentation, visit the Company's website at http://www.entremed.com.

About ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers.  ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, multiple myeloma, and is currently completing a Phase 2 trial for ovarian cancer.  EntreMed is currently conducting a Phase 2 study of ENMD-2076 in triple-negative breast cancer, a Phase 2 study in advanced/metastatic soft tissue sarcoma, and expecting to initiate a Phase 2 study in ovarian clear cell carcinoma.  ENMD-2076 has received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma and acute myeloid leukemia.

About EntreMed
EntreMed is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.  Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer.  EntreMed is currently conducting a Phase 2 stud
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual Meeting
2. Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
3. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
4. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
5. Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting
6. Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes
7. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
8. LipoScience Announces Data Presented at the 2013 American Diabetes Association Meeting
9. New data about the safety and efficacy of linagliptin in adults with type 2 diabetes who have moderate to severe renal impairment presented at ADA
10. Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstroms Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland
11. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... NiQ Health, "the leader ... high level interface capabilities of their CarePlus™ nurse ... The partnership between CarePlus™ and ClinicAll integrates ... patients to choose the most appropriate alarm and ... advanced functionality of CarePlus™ allows patient alarms to ...
(Date:3/30/2015)... , March 30, 2015 DURECT ... it has initiated a multi-dose Phase 1 clinical ... lead molecule in DURECT,s Epigenomic Regulator Program.  DUR-928 ... that may have broad applicability in metabolic diseases ... nonalcoholic steatohepatitis (NASH).  It may also play an ...
(Date:3/30/2015)... Calif. , March 30, 2015  BioPharmX ... on the development of novel drug delivery products ... underserved markets, today announced the appointment of ... retail industry veteran, to its board of directors.  ... it continues to expand its national roll-out of ...
Breaking Medicine Technology:NiQ Health Announces CarePlus(TM) Integration with ClinicAll 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 4BioPharmX Corporation Appoints Stephen Morlock To Its Board Of Directors 2BioPharmX Corporation Appoints Stephen Morlock To Its Board Of Directors 3
... Calif., Sept. 13 QuantaLife, a new life science ... received an NIH grant totaling $6 million over 5 ... detecting methicillin-resistant Staphylococcus aureus (MRSA) infections. The grant, from ... part of the National Institutes of Health, will fund ...
... 13 Pharmacyclics, Inc. (Nasdaq: PCYC ) today reported ... June 30, 2010.   During the fiscal year ended ... No revenue was generated in the fiscal year ended June 30, ... June 30, 2010 was $15.0 million, or $0.31 per share. This ...
Cached Medicine Technology:Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 2Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 3Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 4Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 5Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 6Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 7Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 8Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 9Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 10Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 11Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 12Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 13Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010 14
(Date:3/30/2015)... The National Association of Professional Women ... Professional Woman of the Year. Ms. Rede is recognized ... the largest, most-recognized networking organization of professional women in ... National Association of Professional Women is a powerfully vibrant ... Local Chapters. , “My background of growing up in ...
(Date:3/30/2015)... 2015 This two day ... to provide medical professionals with the information and ... physiology of fascia and its relationship to proper ... This PT CME course will provide ... skills to identify and treat fascial restrictions. Techniques ...
(Date:3/30/2015)... 30, 2015 Hosted by the ... Cares free, two-day dental clinic in Sacramento provided $2 ... 27-28. , In addition to providing free dental ... barriers to care, CDA Cares educates the public and ... the need for an adequately funded dental safety net, ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 With the ... drought stricken areas are scrambling to make sure they ... those individuals to be aware that when Earth loses ... lose water and become dehydrated. Kleyne calls this “body ... , Kleyne talked about weather, body drought and dehydration ...
(Date:3/30/2015)... 2015 Healtheminds, a start-up focusing on ... an innovative, easy to use and engaging online platform, ... about mental health related issues. The first in the ... tobacco and other drugs. , Consumption and use ... These include the toxic effects of excessive intake or ...
Breaking Medicine News(10 mins):Health News:NAPW Announces Patricia Rede, President / Director / Founder of ECHOS of Children: Ending Chaos in Homes of Children, a 2015 Professional Woman of the Year 2Health News:North American Seminars received New Jersey and California approval for Myofascial Release - From Surface to the Depths, a PT and OT Continuing Education Course. 2Health News:CDA Cares Sacramento Dental Clinic Provides $2 Million in Care 2Health News:As California Dry Season Approaches, Risk of Body Drought Increases, Warns Fresh Water Advocate 2Health News:As California Dry Season Approaches, Risk of Body Drought Increases, Warns Fresh Water Advocate 3Health News:HealthEminds Launching Webinar on Drug Dependence 2
... a Cancer Research UK Poll, conducted amongst 4000 people, ... were overweight, has revealed that nearly 26% were obstinately ... shed the extra weight. //Worse still, almost 75% of ... and major health problems, like cancer. ...
... Total Wellbeing Diet recommended by Commonwealth Scientific and ... of colorectal cancer reports Dr. Rosemary Stanton, Nutritionist. ... John Howard to review the risks involved in ... of red meat. Dr. Stanton wants to recommend ...
... reportedly using Nepali soldiers for experiments for finding a ... the US soldiers while serving abroad. Hepatitis E is ... lesser developed nations. //In 1995, the US Armed Forces ... of Walter Reed Army Institute of Research, set up ...
... has been confirmed to be bird flu related as revealed ... to official sources. // If this were again confirmed by ... Indonesian death toll due to bird flu to12. ... contact with dead chickens,' Hariadi Wibisono, the ministry's director of ...
... in the oral feeding habits of infants with breathing ... institution of feeding facilitating techniques. // ,The ... of a feeding tube. Prolonged use of this was ... of gastroesophageal reflux. With the introduction of this new ...
... health in the UK could be hit by a shortage ... primary care reforms mean stalling of their careers and withdrawal ... trust mergers in England under Commissioning a Patient-led NHS has ... ,BMA public health doctors estimate as many as ...
Cached Medicine News:Health News:US Reportedly Experimenting on Nepali Soldiers 2Health News:New Technique Enables Better Nursing Of Robin Sequence Infants 2
... prescription writing, referral letters, chart pulls, transcription, ... ,able to add more appointments to the ... on the exam documentation created by the ... appropriate E&M ,code for the visit - ...
... OPTIX is the perfect solution to assist ... you take control of your practice through the ... paper and pencil. No more impatient clients waiting ... searching for old patient records. No more illegible ...
... ChartLogic is a revolutionary Electronic Medical Office ... and customized for the unique needs of ... benefits of an electronic record system (EMR, ... entire practice to a new level of ...
... Inc is the first truely web-based solution on ... of POC (managed from the lab) and Critical ... design of AegisPOC ensures that all groups have ... programs in the manner best suited to them. ...
Medicine Products: